JO3056B1 - تركيبات { 3-[5-(4-كلورو-فينيل )-أ1-بيرلو [2, 3-ب] بيريدين-3-كربونيل ] -2, 4- ثاني فلورو-فينيل } -أميد بروبان-1-حمض سلفونيك واستخداماتها - Google Patents

تركيبات { 3-[5-(4-كلورو-فينيل )-أ1-بيرلو [2, 3-ب] بيريدين-3-كربونيل ] -2, 4- ثاني فلورو-فينيل } -أميد بروبان-1-حمض سلفونيك واستخداماتها

Info

Publication number
JO3056B1
JO3056B1 JOP/2010/0105A JOP20100105A JO3056B1 JO 3056 B1 JO3056 B1 JO 3056B1 JO P20100105 A JOP20100105 A JO P20100105A JO 3056 B1 JO3056 B1 JO 3056B1
Authority
JO
Jordan
Prior art keywords
phenyl
pyrrolo
difluoro
carbonyl
pyridine
Prior art date
Application number
JOP/2010/0105A
Other languages
English (en)
Inventor
N Ibrahim Prabha
Pudewell Johannes
Desai Dipen
Diodone Ralph
Mahadevan Iyer Raman
Go Zenaida
Lauper Stephan
Conard Visor Gary
Wierschem Frank
Hargovindas Shah Navnit
Wyttenbach Nicole
K Sandhu Harpreet
Mair Hans-Juergen
Original Assignee
Hoffmann La Roche
Plexxikon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Plexxikon Inc filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of JO3056B1 publication Critical patent/JO3056B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

يتعلق الاختراع الحالي بمشتتات صلبة (solid dispersions)، معقدات جزيئية صلبة (solid molecular complexes)، أملاح (salts) ومتعددات شكل متبلورة (crystalline polymorphs) متضمنا propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide
JOP/2010/0105A 2009-04-03 2010-04-01 تركيبات { 3-[5-(4-كلورو-فينيل )-أ1-بيرلو [2, 3-ب] بيريدين-3-كربونيل ] -2, 4- ثاني فلورو-فينيل } -أميد بروبان-1-حمض سلفونيك واستخداماتها JO3056B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16667709P 2009-04-03 2009-04-03
US17605109P 2009-05-06 2009-05-06
EP09175665 2009-11-11

Publications (1)

Publication Number Publication Date
JO3056B1 true JO3056B1 (ar) 2017-03-15

Family

ID=54978682

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2010/0105A JO3056B1 (ar) 2009-04-03 2010-04-01 تركيبات { 3-[5-(4-كلورو-فينيل )-أ1-بيرلو [2, 3-ب] بيريدين-3-كربونيل ] -2, 4- ثاني فلورو-فينيل } -أميد بروبان-1-حمض سلفونيك واستخداماتها

Country Status (3)

Country Link
HR (1) HRP20151156T1 (ar)
IL (1) IL251336B (ar)
JO (1) JO3056B1 (ar)

Also Published As

Publication number Publication date
IL251336A0 (en) 2017-05-29
IL251336B (en) 2020-04-30
HK1168590A1 (zh) 2013-01-04
HRP20151156T1 (hr) 2016-01-01
HK1217195A1 (en) 2016-12-30

Similar Documents

Publication Publication Date Title
MY172424A (en) Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
PL2013208T3 (pl) Pirydyno[3,4-B]pirazynowy
ZA201202024B (en) PROPANE-1-SULFONIC ACID {3-[5-(4-CHLOROPHENYL)-1H-PYRROLO[2,3-b] PYRIDINE-3-CARBONY]-2,4-DIFLUOLOPHENYL}-AMIDE, AS WELL AS USES THEREOF
EG25765A (en) Pyrido [2,3-B] pyrazine derivatives useful as herbicidal compounds
PL2155712T3 (pl) 3-(imidazolilo)-pirazolo[3,4-b]pirydyny
PL2124944T3 (pl) Pochodne pirazolo[3,4-b]pirydyny jako inhibitory fosfodiesterazy
WO2012010538A3 (en) Novel processes for the manufacture of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide
IL226095A (en) History of {4– [5– (1-methyl– h1– pyrazole – 4 – ram) - h1– pyrrolo [3,2– b] pyridin-3-ram] pyrimidin-2-yl} reliable and medications containing them
EP1988155A4 (en) LACTIC ACID BACTERIUM CAPABLE OF PRODUCING AMINO-ACUTE ACID
IL210074A0 (en) Compositions with and process for methylmorpholin-substituted pyrido[2,3-d]pyrimidines
IL207064A0 (en) Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives useful as modulator of nicotinic acetylcholine receptors
PT2040723E (pt) Bactéria do ácido láctico com tolerância ao ácido aumentada
HK1168590A1 (zh) 丙烷-1-磺酸{3-[5-(4-氯-苯基)-1h-吡咯並[2，3-b]吡啶-3-羰基]-2，4-二氟-苯基}-醯胺組合物及其用途
CY1116983T1 (el) Συνθεσεις προπανο-1-σουλφονικου οξεος {3-[5-(4-χλωρο-φαινυλ)-1η-πυρρολο[2,3-β]πυριδινο-3-καρβονυλ]-2,4-διφθορο-φαiνυλ}- αμιδιου και χρησεις αυτων
BR122020005420B8 (pt) forma purificada 1 do polimorfo cristalino do composto i
UA108842C2 (uk) Тверда дисперсія, спосіб її одержання, а також композиція і лікарська форма, що її містять
GB0622263D0 (en) Lactic acid polymers
UA43602U (ru) Применение производных 1,2,3-триазол(1н) -4-карбоновых кислот как ноотропных средств
TH0801002507A (th) 3-(อิมมิดาโซลิล)-ไพราโซโล[3,4-b]ไพริดีน (3-(IMIDAZOLYL)-PYRAZOLO[3,4-B]PYRIDINES)
IL198793A0 (en) Salts of 3-(3-amino-2-(r)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one